OpGen (NASDAQ:OPGN) Research Coverage Started at Wall Street Zen

Wall Street Zen started coverage on shares of OpGen (NASDAQ:OPGN) in a research report sent to investors on Tuesday morning. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Price Performance

OPGN opened at $4.88 on Tuesday. The company has a fifty day moving average of $4.21 and a 200 day moving average of $2.23. OpGen has a fifty-two week low of $0.53 and a fifty-two week high of $5.25.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.